Copyright 2015 OncoRx Pharmaceuticals, Inc. All rights reserved.
Our initial drug products are Orphan Drugs for the treatment of intractable, high-grade gliomas in the brain. Our first drug product(ORX-101)is being developed for Diffuse Intrinsic Pontine Glioma (DIPG), a glioblastoma-like tumor in the brain stem and one of the most resistant of all cancers. DIPG primarily affects young children between 5 and 7 years old. Most of these brain stem tumors cannot be surgically removed because of the remote location and delicate and complex function this area controls. Fewer than 10% of these children will live longer than 18 months from their initial diagnosis. There are no drugs approved for DIPG.
Our second drug product(ORX-102)is being developed for glioblastoma multiforme (GBM), a tumor that is difficult to treat with drug therapy and one which is associated with poor patient survival. Over 90% of patients with astrocytomas have high-grade glioblastoma multiforme tumors when initially diagnosed; and these patients have a median survival of about 1 year from diagnosis with standard-of-care surgery, and radiation therapy with Temodar®. The five-year survival rate for patients with GBM and associated regional metastases using currently available therapies is less than 3%.
Our follow-on drug products for malignant melanoma, pancreatic cancer and estrogen-negative breast cancer with ORX-102 are expected to provide the company with significant growth opportunities in markets that represent over $15 billion annually. Our proprietary drug products will be protected by composition of matter and method of use patents.
Our tumor-activated nanodrug program (ORX-103)is not yet in preclinical development; however, it is expected to provide opportunities for the company in the long term. The company anticipates that drugs using our nanodrug technology will benefit from their small size (~ 2nm), longer systemic half-lives, lower systemic toxicities, improved transport into drug-resistant metastatic tumor cells containing P-gp, and better access to brain tumors. This technology is currently being evaluated for (1) the epigenetic re-activation of tumor suppressor genes in drug-resistant tumors and self-renewing cancer stem cells through their DNMT1, EZH2 and G9a methyltransferase activity; (2) the epigenetic upregulation of MHC(I) molecules on tumors and its influence on the sensitivity to immunotherapy; 3) the delivery of protein kinase inhibitors to brain tumors and drug-resistant metastatic tumors containing the P-gp drug efflux transporter; and 4) targeting the TGF-β pathway in drug-resistant tumors and cancer stem cells.